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This multi-institutional retrospective study
evaluates the association of clinical, patho-
logical, and treatment characteristics with
their outcomes. Their results show total
resection and receiving chemotherapy
adjuvant to radiation or chemoradiation
are most strongly related with improved
progression-free survival (PFS) and over-
all survival. For higher risk incom-
pletely resected patients, temozolomide
(TMZ) use and treatment intensification
with concurrent chemoradiation, adjuvant
chemotherapy, and higher radiation dose
were associated with improved outcomes.
It is a well written and conducted paper
about a remarkable challenge to neuro-
surgeon and pediatric oncologists. Little
progress has been made in the outcome
of these tumors in the last four decades.
Outcome remains dismal with <20% of
patients surviving (1). The degree of sur-
gical resection is one of the most impor-
tant clinical prognostic factors known in
children with supratentorial high-grade
gliomas (HGGs), independent of location,
histology, and age as the authors show (2).
Chemotherapy was first introduced into
the treatment schema for children with
newly diagnosed HGG in 1970s. One
the first randomized study was CCG-943
trial, in which children with newly diag-
nosed HGG were randomized to receive
either focal radiation therapy alone to a
dose of 54 Gy or the same radiotherapy
with a combination of concomitant and
maintenance chemotherapy. Patients ran-
domized to receive chemotherapy were
given weekly vincristine during radiation
followed by eight maintenance chemother-
apy cycles consisting of prednisone, lomus-
tine, and vincristine (PCV) each given
approximately 6 weeks apart (3). This
important study showed that treatment
with chemotherapy prolonged the survival
and event-free survival. The Children’s
Cancer Group (CCG) study-945 showed
that children with HGG who underwent
a surgical resection of 90% or greater
had a PFS of 35± 7% as compared to a
5-year PFS of 17± 4% in patients who
did not (4). The authors did not refer
any benefit to the treatment of high-
grade astrocytomas in children with eight-
drugs in 1-day chemotherapy compared
with CCNU, vincristine, and prednisone.
Extent of tumor resection and histopatho-
logic diagnosis were significant prognos-
tic variables (4). The CCG-945 trial also
looked at a variety of molecular and
cytogenetic markers in an effort to bet-
ter define prognostic variables in pedi-
atric HGG.
Currently, the efficacy of chemothera-
peutic compounds against pediatric brain
tumors is unsatisfactory. Efficacy of TMZ
has generally been found to be non-
superior to other chemotherapeutic agents
in pediatric HGG, and various stud-
ies in children have shown no benefit
over conventional treatment (5). Cilen-
gitide was well tolerated in pediatric
HGG, yet had modest anti-tumor activ-
ity as a single agent (6). However, cilen-
gitide in combination with radiation and
chemotherapy, TMZ, has shown syner-
gistic activity (7). Phase I or II stud-
ies of small molecules that target spe-
cific pathways or proteins in the cancer
cells such as gefitinib (8), imatinib (9),
cloretazine (10), tipifarnib (11), erlotinib
(12), and nimotuzumab (13) disclosed
no efficacy, despite occasional remarks of
stable disease (1). Recently, fractionated
schedules of drug administration using
smaller doses than the maximum tolerated
dose (metronomic schedules) have been
reported that might enhance the antian-
giogenic activity of some chemotherapeu-
tic agents (14). Metronomic chemother-
apy shows potential advantages in pediatric
brain tumors treatment, including pri-
mary effect on the host cells of the
tumor microenvironment, the possibility
of greater long-term efficacy and toler-
ability than conventional cytotoxic ther-
apy (14).
In recent years, important advances
in the comprehension of the molecular
characteristics of HGG in pediatric age
have been made. Initial genomic stud-
ies of pediatric HGG disclosed signifi-
cant differences compared to tumors from
adult patients suggesting the existence of
molecularly diverse subsets within pedi-
atric cohorts. Data about the interactions
between genetic alterations and changes in
DNA methylation, histone modifications,
chromatin remodeling, and gene expres-
sion contribute to explain pathogenesis of
malignant gliomas. Adult HGG are char-
acterized by IDH1, PTEN, and/or EGFR
aberrations; whereas pediatric HGG often
harbors PDGFR amplification. PDGFR
amplification or overexpression represents
the most common abnormality of HGG

























































Caffo Pediatric high grade gliomas
in pediatric patients (15). BRAF and
CDKN2A mutations have been reported to
characterize HGG in a subset of pediatric
patients, although BRAF abnormalities are
not as frequently as described in childhood
low-grade glioma (15). Schwartzentruber
et al. reported in a large cohort of gliomas
of various grades and histologies H3F3A
mutations to be prevalent in children
and young adults affected by malignant
gliomas (16). Mutations of genes H3F3A
and HIST1H3B are epigenetic and play a
role in chromatin remodeling (17). Muta-
tions in IDH1 or IDH2 are exceptional in
pediatric patients but occur in the major-
ity of adult patients with HGG. A study
of pediatric primary HGG from the Chil-
dren’s Oncology Group observed IDH1
mutations in 7 of 43 tumors. Remarkably,
all of these IDH1 mutations occurred in
children ≥14 years old, with none occur-
ring in younger children. No IDH2 muta-
tions were observed (18). IDH1 muta-
tions at codon 132 strongly differentiate
adult secondary from primary glioblas-
toma, with frequencies of 85% compared
with 5%. Paugh et al. sequenced IDH1
exon 4, containing codon 132, from 78
pediatric HGGs and 11 pediatric low-grade
gliomas, and no codon 132 mutations were
detected (15).
The recent genomic groundbreaking
work added tremendously to our under-
standing of the mutational landscape
of pediatric HGG, bringing to light
new, potentially targetable pathways, and
promise of more effective therapies. In
light of these observations, new trials and
emerging data about pediatric HGG could
improve the outcome of HGG in children
and young adults.
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